{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-018449","form_type":"8-K","ticker":"IONS","cik":"0000874015","company_name":"IONIS PHARMACEUTICALS INC","filed_at":"2024-04-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.233284+00:00","generated_at":"2026-06-04T01:37:35.470378+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Ionis Phase 3 Balance study of olezarsen meets primary endpoint; reduces acute pancreatitis in FCS","bullets":["Olezarsen 80 mg reduced fasting triglycerides by 44% vs placebo at 6 months (p<0.001).","Acute pancreatitis events: 1 event in 80 mg group vs 11 in placebo over 12 months.","All-cause hospitalizations reduced by 84% (placebo-adjusted) from baseline to 12 months.","No serious treatment-emergent AEs related to olezarsen; serious AEs 14% (80 mg) vs 39% placebo.","Ionis to pursue regulatory approval for first potential FCS treatment in U.S.; data published in NEJM."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-018449","json":"https://secwatch.observer/filing/0001140361-24-018449.json","markdown":"https://secwatch.observer/filing/0001140361-24-018449.md","text":"https://secwatch.observer/filing/0001140361-24-018449.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/874015/000114036124018449/0001140361-24-018449-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874015/000114036124018449/ef20026226_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T01:37:35.470378+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}